Summary of Pelthos Therapeutics FY Conference Call (March 23, 2026) Company Overview - **Company**: Pelthos Therapeutics (NYSEAM:PTHS) - **Lead Product**: ZELSUVMI, a topical nitric oxide releasing product for treating molluscum contagiosum in patients aged one year and older [5][7] Key Points Company Background and Capitalization - Pelthos was formed from a merger with Channel Therapeutics on July 1, 2025, after raising $50 million through a PIPE [5] - The company trades on the NYSE under the ticker PTHS, with a current market cap of approximately $200 million [6] Product Information - **ZELSUVMI**: - First FDA-approved at-home treatment for molluscum contagiosum, allowing for daily application over 12 weeks [8] - Addresses a significant unmet need as traditional treatments involve painful procedures [7][10] Financial Performance - Prescription volume increased by 129% from Q3 to Q4, with net revenue rising from $7.1 million in Q3 to $9.1 million in Q4 [13][14] - The company has over 4,200 unique prescribers since the product launch [14] - Payer access is favorable, with 70% of prescriptions covered by commercial insurance and 99% by Medicaid [15][16] - Gross to net ratio improved from 25.3% in Q3 to 28.7% in Q4, with expectations to reach mid- to upper 30s% in 2026 [18] Sales Strategy and Market Access - The sales force is approximately 64 representatives, focusing on both dermatologists and pediatricians [19] - The company plans to leverage existing sales channels for new products, Xepi and Xeglyze, which target pediatric conditions [20][25] New Product Acquisitions - **Xepi**: - Targets impetigo, with a significant market need due to resistance to current treatments [21] - Expected to launch in early 2027 [24] - **Xeglyze**: - Aimed at treating head lice, with a unique dual-action formula [22] - Planned launch in the latter half of Q2 2027 [25] Future Outlook - Revenue guidance for ZELSUVMI is projected at $175 million by 2028, with a current consensus estimate of just over $60 million for the year [57] - The company is comfortable with its cash position, having raised $50 million in equity and additional funds through convertible debt [55][56] Intellectual Property and Market Exclusivity - ZELSUVMI has patent protection until 2035, with potential extensions into 2037 [40] - Xepi and Xeglyze have exclusivity until early 2032 and 2034, respectively [41] Strategic Focus - The primary focus remains on successfully launching ZELSUVMI, with plans to evaluate additional indications for the NITRICIL platform in the future [47][49] Additional Insights - The company emphasizes the importance of executing its current business plan before pursuing further acquisitions or expansions [47] - There is a noted prevalence of "super lice," which enhances the market potential for Xeglyze [22]

Corporate Presentation M A R C H 2 0 2 6 1 White 255 255 255 Background & Text Dark Grey 51 51 51 Pale Grey 225 225 225 Blue 0 61 166 Accents Blue 0 61 166 Sky Blue 0 154 222 Grey 137 138 141 Lime Green 164 203 95 Dark Teal 25 155 155 Title Case Headers Montserrat Bold Montserrat Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws ...

Summary of Pelthos Therapeutics FY Conference Call Company Overview - **Company Name**: Pelthos Therapeutics (NYSEAM:PTHS) - **Industry**: Biopharmaceuticals, specifically focused on pediatric cutaneous infectious diseases - **Ticker Symbol**: PTHS - **Market Capitalization**: Approximately $200 million [4] - **Shares Outstanding**: 8.9 million common shares [4] Key Products and Developments - **Lead Product**: ZELSUVMI, launched in July 2025, indicated for the treatment of molluscum contagiosum in patients aged 1 year and older [3][7] - **Recent Acquisitions**: - **Xepi**: Acquired in late 2025, expected launch in late 2026, treats impetigo [3][29] - **Xeglyze**: Acquired for $1.8 million, FDA-approved for head lice treatment, expected launch in mid-2027 [30][31] Financial Highlights - **Cash Position**: $14.2 million at Q3 close, raised an additional $18 million in a convertible note [4] - **Revenue Generation**: - Q3 2025: 2,700 units of ZELSUVMI dispensed, generating $7.1 million in net revenue [24] - Q4 2025: 129% growth in units quarter-over-quarter [24] - Anticipated gross-to-net (GTN) in Q4 expected to rise to the high 30% range [25] Market Strategy and Sales Performance - **Sales Force**: Initially launched with 50 representatives, expanded to 64 territories by March [21][22] - **Target Audience**: Focus on dermatologists, pediatric dermatologists, and pediatricians, covering approximately 10,000 top molluscum treaters [22] - **Digital Marketing**: Successful YouTube promotional video with over 3.5 million views [23] Clinical Insights and Product Efficacy - **ZELSUVMI Efficacy**: - B-SIMPLE4 trial showed about one-third of patients achieved complete clearance at 12 weeks [19] - 80% of parents found the treatment clinically meaningful even without complete clearance [20] - **Safety Profile**: Common side effects include mild application site pain (12%) and moderate pain (6%) [17] Market Challenges and Opportunities - **Molluscum Contagiosum**: High prevalence among children, with 73% of affected children going untreated [10] - **Treatment Landscape**: Traditional treatments often require multiple painful office visits; ZELSUVMI offers a home-based solution [16][17] - **Resistance Issues**: Concerns over mupirocin resistance in treating impetigo, presenting an opportunity for Xepi [30] Management Team and Experience - **CEO**: Over 30 years in the pharmaceutical industry, with a history of successful exits [5] - **Board Composition**: Includes experienced executives from various pharmaceutical companies, enhancing strategic direction [6] Future Outlook - **Product Pipeline**: Focus on maximizing ZELSUVMI's market potential before launching Xepi and Xeglyze [32] - **Potential Collaborations**: Opportunities to work with Ligand on clinical stage programs for the NITRICIL platform [37] - **Financial Position**: Strong capital position to support growth and potential acquisitions [36] Conclusion Pelthos Therapeutics is positioned for growth with its innovative product ZELSUVMI, a strong management team, and strategic acquisitions. The company is focused on addressing unmet needs in pediatric infectious diseases while navigating market challenges and leveraging digital marketing strategies for enhanced outreach.